Henry Schein to distribute DIPRO blood test:
This article was originally published in Clinica
Executive Summary
Henry Schein has signed an exclusive agreement with the US branch of the diagnostic company Dipro to market the company's Hemdetect occult blood test kit. Dipro's US branch is an offshoot of the Austria-based company, and it was set up to distribute the company's products in north America. The blood test, which Henry Schein added to its catalogue in the autumn of 1996, has been available in Europe for the past three years.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.